about
Pro-inflammatory chemokine CCL2 (MCP-1) promotes healing in diabetic wounds by restoring the macrophage responseIFN-λ: A New Inducer of Local Immunity against Cancer and InfectionsBone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesInterleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resectionMalignancies in HIV/AIDS: from epidemiology to therapeutic challenges.Immune modulation of HIV replication: relevance to HIV immuno- and neuro-pathogenesis.HSP70i is a critical component of the immune response leading to vitiligoConcerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus.Oncolytic viruses: a new class of immunotherapy drugs.Talimogene laherparepvec (T-VEC) as cancer immunotherapy.IFN-lambda therapy: current status and future perspectives.IFN-λ cancer immunotherapy: new kid on the block.Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice.CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV.Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death.NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responses.CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells.High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis.Multiple populations of T lymphocytes are distinguished by the level of CD4 and CD8 coexpression and require individual consideration.Infection: a Cause of and Cure for Cancer.Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer.A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R(-/-) Hu-PBMC Mice.Double-Humanized Mouse Model to Study Bone Morphogenetic Protein (BMP) Signaling in Tumor XenograftsOncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanomaSafety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administrationIntegrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment
P50
Q27316027-EA4D27D1-03DE-443F-9C43-A9FDA8B13499Q28072995-D236A0C3-534C-4C25-95AA-0C35DEEC3FDFQ33605113-12FB339A-77BF-4267-AF20-3B92BD3A4D9CQ33606166-C3A519D7-771D-422D-9FAA-77E19160A4FEQ33637231-ADF381C7-D533-48C2-9DC4-73EFC3EDB8FEQ33774512-4F7C6BF1-7C40-43C5-9D3B-2C6CB98A0A23Q34625208-97C929EC-3895-4BC3-970C-E9824A819037Q35850380-6A4EB0D7-6C07-4EDF-BC5E-9BC92B95D62FQ35949959-D54C17E4-12AD-4FA1-9B46-65EC1A7D9DC8Q36871508-51040D77-EF53-4E3D-B894-4A9482245FF5Q37580211-332F4DBB-AFA6-468B-B3FA-8FB93C802A9DQ37730623-E0E456B2-2E77-428A-9A66-FF2C9B5A2C69Q38577450-FBBC408B-8C82-49F0-BF39-0EB56DE2B979Q38612926-9F462932-0CDA-42E7-A22D-6B7BEB7C80D2Q38629043-736FA3C7-19C9-4260-8507-1E19E81CB4D1Q38887297-2ECA9150-1544-42AD-9413-9C296BBFCF1BQ39002223-6C63E5C0-82E3-4F39-955E-3AAD60864B56Q39018737-2335FE10-CA0A-443C-8280-3466AD6E504AQ39633119-D404CC87-E112-40CC-86F3-1B3882E165EBQ40498026-A369F22E-2740-4BE4-BC7B-93CE33348278Q40852288-488EB5F4-C976-48EC-B65A-C52BC88890EDQ41684403-FC707839-88B2-46EA-9699-843070F91568Q41706958-2BF26E06-CBB7-4518-A7F1-FF88DB389929Q42237961-69963A21-4CF5-4478-99A1-BEFB20AE20ECQ42323649-86F4A3BA-378F-413F-88F6-3D453A810AD6Q42971742-3870CAA6-E036-4EFD-8972-361B25BC33D2Q46870331-CA71DD31-5062-4669-8B9B-B62C33102F17Q47142729-548B0B78-844A-4DC8-930B-C3F75CE3DAA0Q47557461-0E3E8230-4369-4EE6-AD91-74FAAD0BB4B9Q49907440-9A408168-CBB3-48A5-AD5C-B6CBD1623787Q51090372-D24244CB-F111-4358-A4B9-54E3EB792F69Q51377244-B36B77A7-B9CC-412F-8C84-0CF31FE8F676Q52603777-B0C8E5C1-8E65-4E86-88AD-348171394731Q52658085-426C73F5-FFFD-410D-9EF5-50C01E8C80C2Q52746279-8CF64929-5D13-40B3-9BA1-53F4507D1BC0Q53553535-F09C2200-1D94-4E29-BAF0-414DAA75D64EQ58543809-43EB88C1-269A-48CA-B4F1-D2020D5EEC0CQ64268041-EDDE8409-31D7-47D9-8AC0-3E591D79CA03Q64279540-0506932E-BE14-46E0-A72D-882E42566563Q88611119-678F766E-BC14-43F4-A309-248C933E1FF4
P50
description
researcher ORCID ID = 0000-0001-8844-6493
@en
wetenschapper
@nl
name
Andrew Zloza
@ast
Andrew Zloza
@en
Andrew Zloza
@es
Andrew Zloza
@nl
type
label
Andrew Zloza
@ast
Andrew Zloza
@en
Andrew Zloza
@es
Andrew Zloza
@nl
prefLabel
Andrew Zloza
@ast
Andrew Zloza
@en
Andrew Zloza
@es
Andrew Zloza
@nl
P1153
6508033744
P31
P496
0000-0001-8844-6493